Label-free techniques for Drug Discovery:

SPR Mass Spectrometry

This webinar took place on August 13th 2018

Register to download slides & media

Please fill out the form to stream our webinar
"Label-free techniques for Drug Discovery: Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening"

First Name: *

Last Name: *

Email Address: *

Company: *

Postal Code: *

City: *

Country: *

State: *

Telephone:

Industry: *

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?: *

Marketing Consent

Following of our interaction with you, Bruker Daltonics and its affiliates within the Bruker group (“Bruker”) would like to be able to stay in contact with you and inform you about the latest technological achievements and upcoming events as well as the products and services offered by Bruker. If you are interested in hearing from us in the future, we will need your consent in accordance with applicable data protection laws to be allowed to engage in marketing activities using your contact information.

To view the promises that we make to you regarding your personal information, please view Bruker`s privacy policy. For questions related to privacy, please send your inquiry to privacy@bruker.com. If you prefer not to receive promotional e-mails from Bruker in the future, you can unsubscribe at any time.

I agree that Bruker can use my contact information as described in this Marketing Consent form.

Media

Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening

Webinar Overview

The webinar will update on latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed.

Key Topics

Primary and Secondary Screening in Drug Discovery
Label-free technologies to reduce artefacts / importance of controls in SPR experiments
Kinetic characterization: Determination of KDon- and KDoff-rates of compounds (SPR)
Automation strategies to maximize throughput (SPR and MALDI)

Speakers

Dr. Meike Hamester

Director Small Molecule Pharma Business

Dr. Meike Hamester studied chemistry at the University of Hamburg, Germany. She worked 18 years in the field of mass spectrometry at Thermo Fisher Scientific. Since 2012 Meike works for BRUKER Daltonik in Bremen.

Dipl.-Ing. Sven Malik

Senior Application Specialist

Dipl. -Ing. Sven Malik studied Bioprocess-Engineering at TU Dresden. He worked 8 years in the field of surface plasmon resonance. Since 2012 Sven worked for Sierra Sensors GmbH (now Bruker).